1Haubner R,Wester H J,Burkhart F,et al.Glycosylated RGD-containing peptides:tracer for tumor targeting and angiogenesis imaging with improved biokinetics[J].J Nucl Med,2001,42 (2):326-336.
2Clezardin P.Recent insights into the role of integrins in cancer metastasis[J].Cellular and Molecular Life Sciences,1998,4(6):541-548.
3Thumshirn G,Hersel U,Goodman S L,et al.Multimeric cyclic RGD peptides as potential tools for tumor targeting:solidphase peptide synthesis and chemoselective oxime ligation[J].Chem Eur J,2003,9 (12):2717-2725.
4Chen X Y,Liu S,Hou Y P,et al.MicroPET imaging of breast cancer αv-integrin expression with 64Cu-labeled dimeric RGD peptides[J].Molecular Imaging and Biology,2004,6(5):350-359.
5Chen X Y,Tobme M,Park R,et al.Micro-PET imaging ofαvβ3-integrin expression with 18F-labeled dimeric RGD peptide[J].Molecular Imaging,2004,(2):96-104.
6Haubner R,Wester H R,Reuning U,et al.Radiolabeled αvβ3integrin antagonists:a new class of tracers for tumor targting[J].J Nucl Med,1999,40 (6):1061-1071.
7Janssen M,Oyen W J,Massuger L F,et al.Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting[J].Cancer Biother Radiopharm,2002,17(6):641-646.
8Sivolapenko G B,Skarlos D,Pectasides D,et al.Imaging of metastatic melanoma utilising a technetium-99m labelled RGDcontaining synthetic peptide[J].Eur J Nucl Med,1998,25(10):1383-1389.
9Pfaff M,Tangemann K,Muller B,et al.Selective recognition of cyclic RGD peptides of NMR defined conformation by alpha Ⅱb beta 3,alpha V beta 3,and alpha5 beta 1 integrins[J].J Biol Chem,1994,269 (32):20233-20238.
10Haubner R,Gratias R,Dietenbach B,et al.Structural and functional aspects of RGD-containing cyclic pentapeptides as highly potent and selective integrin αvβ3 antagonists[J].J Am Chem Soc,1996,118 (32):7461-7472.
